Who Qualifies for Medicare's $50 Weight-Loss Drug Copay?

For as long as GLP-1 drugs have existed, Medicare has drawn a hard line. If you were prescribed one for diabetes, it was covered. If you were prescribed the exact same drug for weight loss, you paid full price, often $700 or more a month, or you didn't get it at all. The GLP-1 Bridge program changes that for some patients.

As of July 1, 2026, a new program called the Medicare GLP-1 Bridge lets eligible beneficiaries get certain weight-loss medications for a flat $50 a month. It's the first time in the program's history that Medicare has helped pay for a drug prescribed purely for obesity. For a family managing an aging parent's health, the eligibility rules and end date matter.

What changed on July 1

CMS is running the Bridge as an 18-month pilot, lasting from July 1, 2026, through December 31, 2027. It's not a permanent change to Medicare law. Instead, it uses a provision that lets the federal government test new coverage approaches on a temporary basis, which is also why nobody can promise what happens after 2027.

Three medications are covered under the pilot:

• Wegovy (Novo Nordisk): injectable and pill forms
• Zepbound KwikPen (Eli Lilly): weekly injection
• Foundayo (Eli Lilly): a newer daily weight-loss pill, FDA-approved earlier this year

Without coverage, these drugs are expensive. Cash prices run anywhere from roughly $149 to $699 a month depending on the drug and dose. The Bridge program flattens all of that into one $50 monthly copay, and that price doesn't climb even if a patient needs a higher dose over time.

Who qualifies

This isn't available to every Medicare beneficiary who wants to lose weight. You need Part D coverage, and your doctor has to submit a prior authorization confirming you meet specific clinical criteria based on your BMI and health history at the time you started (or start) the medication. The thresholds are:

• BMI of 35 or higher qualifies automatically
• BMI of 30 or higher, plus a history of heart failure, uncontrolled hypertension, or chronic kidney disease
• BMI of 27 or higher, plus prediabetes, a prior heart attack or stroke, or symptomatic peripheral artery disease

KFF estimates around 3.8 millionMedicare beneficiaries meet these criteria. That's a large group, but it also means plenty of people who are overweight and want help won't clear the bar.

There's a wrinkle for anyone already on a GLP-1. If you're taking one for type 2 diabetes, cardiovascular risk reduction, or sleep apnea, you stay on your regular Part D plan and pay whatever that plan charges, which may well be more than $50. And if you already started a GLP-1 for weight loss before July 1, your doctor has to attest that you met the BMI criteria back when you startedtreatment, not necessarily where you're at now. Someone who began at a BMI of 37 and has since lost weight down to 34 would still qualify, because the bar is measured at the starting point.

What the $50 copay does not cover

There are a few details to know before counting on the $50 price:

• The $50 doesn't count toward your Part D deductible or your $2,100 annual out-of-pocket cap, because the Bridge program runs outside standard Part D coverage.
• You can't stack manufacturer coupons or other discounts on top of the $50 price.
• If you receive Extra Help (the Medicare low-income subsidy), that assistance doesn't apply here. For someone living on a fixed Social Security check, $50 a month is still real money.

How the process works

Getting access isn't as simple as showing a Medicare card at the pharmacy counter. Your doctor submits a prior authorization request through a centralized system CMS built with Humana as the contractor, the same infrastructure used for another Medicare drug program. Once that's approved, the pharmacy fills the prescription at the flat $50 rate. Doctors don't need to be enrolled as Medicare providers to submit the request, which was meant to keep the process from bottlenecking at the physician level.

In practice, the paperwork has become the sticking point. An August 2026 analysis in STAT described the administrative load on primary care as rivaling the clinical work itself: verifying BMI criteria, documenting obesity-related conditions and prior weight-management attempts, filing insurer-specific forms, and resubmitting when a request is denied or delayed. Some smaller practices, it noted, may decide that helping patients enroll isn't sustainable and stop assisting altogether. A benefit that exists on paper isn't the same as one a family can actually get, especially without the time or support to chase the paperwork.

Why the program is temporary

CMS originally proposed a longer-term plan that would have shifted GLP-1 costs onto private insurers starting later this year, but not enough insurers signed on by the deadline. So the Bridge got stretched from a planned six months to 18, buying more time to figure out what comes next. Nobody, including CMS, has published what the extension is actually going to cost. KFF's Juliette Cubanski put it plainly: it's likely to run into the billions annually, and "there's no clear path forward yet" for what happens once the pilot ends in December 2027. There's also a well-documented pattern of people regaining weight after stopping GLP-1s, so a program built around a hard 2027 cutoff carries real stakes for the people who start relying on these drugs now.

What this means if you're managing a parent's care

If you're the one keeping track of a parent's or spouse's medications, appointments, and paperwork, this is the kind of policy change that's easy to miss until a pharmacy bill lands in the mail. A few practical steps:

These details can get lost when a family is juggling multiple doctors, prescriptions, and insurance plans across different people. A weight-loss drug that costs $50 one month and $500 the next because a prior authorization lapses can put treatment out of reach.

What to ask the prescriber

For the first time, Medicare is treating obesity as a condition worth covering on its own, not just as a side effect of diabetes or heart disease. For the roughly 3.8 million beneficiaries who qualify, it could mean the difference between affording treatment and going without it. This is a temporary pilot with a hard end date, specific drugs, and real gaps for anyone who doesn't meet the BMI thresholds or who's already covered under a different indication. If a GLP-1 for weight loss is on the table for you or someone you're caring for, ask the prescriber about eligibility and prior authorization before going to the pharmacy.